JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Published:2012-03 Issue:9 Volume:366 Page:787-798
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Harrison Claire,Kiladjian Jean-Jacques,Al-Ali Haifa Kathrin,Gisslinger Heinz,Waltzman Roger,Stalbovskaya Viktoriya,McQuitty Mari,Hunter Deborah S.,Levy Richard,Knoops Laurent,Cervantes Francisco,Vannucchi Alessandro M.,Barbui Tiziano,Barosi Giovanni

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1110556

Cited by 1523 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and Pharmacologic Inhibition of JAK1/2 Antagonizes Cardiac Fibrosis;Circulation;2024-09-10

2. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

3. Advances in Stem Cell Transplantation for Myelofibrosis;Current Hematologic Malignancy Reports;2024-09-06

4. Biological Evaluations and Computer-Aided Approaches of Janus Kinases 2 and 3 Inhibitors for Cancer Treatment: A Review;Pharmaceutics;2024-09-04

5. Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis;Cancer Reports;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP